US · Healthcare · Biotechnology
EPS came in at -1.77 against a street estimate of -0.89 — a miss of 98.9%.
Analysts rate Zenas BioPharma, Inc. Common Stock a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $47.00.
| Fund | Stake |
|---|---|
| FMR Inc | 13.93% |
| SR ONE CAPITAL MANAGEMENT, LP | 7.73% |
| NEA Management Company, LLC | 6.17% |
| Enavate Sciences GP, LLC | 6.01% |
| Federated Hermes Inc | 4.78% |
| Polar Capital Holdings PLC | 3.91% |
| Capital Research & Mgmt Co - Division 3 | 3.84% |
| Fairmount Funds Management LLC | 3.62% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 ZENAS BIOPHARMA, INC. — FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash & Investments: $643.9 million in liquid assets (c | 2026-08-13 |
| Results announced · Q3 2026 ZENAS BIOPHARMA Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and investments: $673.9 million as of June 30, 2026 • Q2 | 2026-08-13 |
| Quarterly report · Q1 2026 ZENAS BIOPHARM INC. - Q1 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash Position: $500.2 million as of March 31, 2026 (up from $110.6 mil | 2026-05-13 |
| Results announced · Q2 2026 ZENAS BIOPHARM Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and investments: $718.5 million as of March 31, 2026 (vs. | 2026-05-13 |
| Material agreement · Q1 2026 ZENAS BIOPHARMA, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company completed $200,000,000 convertible notes offering on March 31, 2026 • Raised $5, | 2026-03-31 |
| Annual report FY2025 ZENAS BIOPHARM, INC. — 2025 ANNUAL REPORT SUMMARY HEADLINE NUMBERS • Market cap: $259.3 million (as of June 30, 2025 at $9.69/share); 57,361,260 sha | 2026-03-16 |
| Results announced · Q1 2026 ZENAS BIOPHARMACEUTICAL COMPANY SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and investments: $360.5 million as of December 31, 2025 • Net loss | 2026-03-16 |
| Proxy statement · Q2 2026 ZENAS BIOPHARMA, INC. – 2026 PROXY STATEMENT SUMMARY EXECUTIVE COMPENSATION • CEO Total Compensation (Leon O. Moulder, Jr.): The document does not p | 2026-03-16 |
Readable in the app.
| Announcement | Date |
|---|---|
| Exclusive license agreement for three drug development programs Zenas BioPharma entered into a licensing agreement with InnoCare Pharma on October 7, 2025, acquiring exclusive rights to develop and commercialize three drug candidates. The deal includes: | 2025-10-08 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Zenas BioPharma, Inc. Common Stock — free to start.
Google PlayApp StoreData updated 2026-09-18.